Transcription-induced DNA double strand breaks: Both oncogenic force and potential therapeutic target?

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 3858-3864

  Haffner, Michael C ^a   De Marzo, Angelo M ^a   Meeker, Alan K ^a   Nelson, William G ^a   Yegnasubramanian, Srinivasan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; ATM PROTEIN; DIETHYLSTILBESTROL; DNA DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN; ESTROGEN RECEPTOR; ETOPOSIDE; GONADORELIN AGONIST; GYRASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN TOP2B; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERG GENE; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TMPRSS2 GENE; TRANSCRIPTION INITIATION;

ANIMALS; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; GENE REARRANGEMENT; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, ESTROGEN; TRANSCRIPTION, GENETIC; TRANSLATIONAL RESEARCH;

EID: 79959189181     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2044     Document Type: Review

References (63)

1. Chakalova L, Fraser P. Organization of transcription. Cold Spring Harb Perspect Biol 2010;2:a000729.
2. Cook PR. Predicting three-dimensional genome structure from transcriptional activity. Nat Genet 2002;32:347-52. (Pubitemid 35266106)
3. Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009;326:289-93.
4. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009;462:58-64.
5. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-75.
6. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006;312:1798-802. (Pubitemid 43962898)
7. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-83.
8. Maldonado E, Shiekhattar R, Sheldon M, Cho H, Drapkin R, Rickert P, et al. A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature 1996;381:86-9. (Pubitemid 26130009)
9. Mayeur GL, Kung WJ, Martinez A, Izumiya C, Chen DJ, Kung HJ. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem 2005;280:10827-33. (Pubitemid 40395946)
10. Mo X, Dynan WS. Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites. Mol Cell Biol 2002;22:8088-99. (Pubitemid 35217316)
11. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008;319:202-6.
12. Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell 2009;136:1056-72.
13. Webb CF, Eneff KL, Drake FH. A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5′ of an immunoglobulin promoter. Nucleic Acids Res 1993;21:4363-8. (Pubitemid 23279029)
14. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009;37:738-48.
15. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40. (Pubitemid 34685700)
16. Nelson WG, Liu LF, Coffey DS. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 1986;322:187-9. (Pubitemid 16005460)
17. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
18. Fortune JM, Lavrukhin OV, Gurnon JR, Van Etten JL, Lloyd RS, Osheroff N. Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity. J Biol Chem 2001;276:24401-8.
19. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003;3:321-38.
20. Williamson LM, Lees-Miller SP. Estrogen receptor {alpha}-mediated transcription induces cell cycle-dependent DNA double strand breaks. Carcinogenesis 2011;32:279-85.
21. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-8. (Pubitemid 26428076)
22. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
23. Li TK, Chen AY, Yu C, Mao Y, Wang H, Liu LF. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress. Genes Dev 1999;13:1553-60. (Pubitemid 29297923)
24. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci U S A 2000;97:4790-5. (Pubitemid 30238636)
25. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990;50:6919-24. (Pubitemid 20361091)
26. Zhang H, D'Arpa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990;2:23-7.
27. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A 2007;104:11014-9. (Pubitemid 47175218)
28. Kim MS, Kondo T, Takada I, Youn MY, Yamamoto Y, Takahashi S, et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009;461:1007-12.
29. Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008;452:45-50. (Pubitemid 351355084)
30. Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet 2010;11:819-29.
31. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-5. (Pubitemid 351354863)
32. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-45. (Pubitemid 46480968)
33. Aplan PD. Causes of oncogenic chromosomal translocation. Trends Genet 2006;22:46-55. (Pubitemid 43011997)
34. Rowley JD. Chromosomal translocations: revisited yet again. Blood 2008;112:2183-9.
35. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
36. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
37. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
38. Mathas S, Kreher S, Meaburn KJ, Jöhrens K, Lamprecht B, Assaf C, et al. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A 2009;106:5831-6.
39. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8. (Pubitemid 47165141)
40. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65. (Pubitemid 26119117)
41. Marker PC. Does prostate cancer co-opt the developmental program? Differentiation 2008;76:736-44.
42. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006;444:638-42. (Pubitemid 44864443)
43. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9. (Pubitemid 29003936)
44. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
45. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer 2010;10:205-12.
46. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 1996;93:11802-7. (Pubitemid 26347204)
47. Prout GR Jr, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967;20:1871-8.
48. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005;65:2082-4. (Pubitemid 40490112)
49. Mathew P. Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial. Ann Oncol 2008;19:395-6. (Pubitemid 351201727)
50. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133-6. (Pubitemid 35012319)
51. Lewis JS, Cheng D, Jordan VC. Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004;90:944-9. (Pubitemid 38495809)
52. Feltquate D, Nordquist L, Eicher C, Morris M, Smaletz O, Slovin S, et al. Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res 2006;12:7414-21. (Pubitemid 46095416)
53. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.
54. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinumfree interval. J Clin Oncol 2010;28:2512-9.
55. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
56. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22.
57. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005;24:949-61. (Pubitemid 40313872)
58. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2003;2:1257-64.
59. Ljungman M. Targeting the DNA damage response in cancer. Chem Rev 2009;109:2929-50.
60. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. A human 50-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009;461:674-8.
61. Zeng Z, Cortes-Ledesma F, El-Khamisy SF, Caldecott KW. TDP2/TTRAP is the major 50-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J Biol Chem 2010;286:403-9.
62. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-50.
63. Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010;70:1600-7.